SeaStar Medical Holding Corporation announced that new data highlighting the cost savings of its QUELIMMUNE Pediatric therapeutic device were presented at the American Society of Nephrology’s (ASN) Kidney Week 2024. The analysis revealed that the hospitalization cost of pediatric patients with AKI requiring CRRT, a majority of whom were septic, was $461,736 per hospitalization.
Data from the Kids’ Inpatient Database and SeaStar Medical’s SCD-PED studies indicated that hospitalization costs were significantly lower for critically ill children with AKI on CRRT treated with QUELIMMUNE. Treatment with QUELIMMUNE resulted in a projected cost savings of approximately $30,000 per hospitalization, primarily driven by a lower expected death rate and shorter length of stay compared to standard of care.
Additional benefits included cost neutrality for institutions starting at 6 days of QUELIMMUNE therapy, supported by a 77% survival rate in children treated with QUELIMMUNE versus a control survival rate of approximately 50%. The combined observed outcomes also showed 0% dialysis dependence at day 60 from the SCD PED-01 and SCD-PED-02 studies, illustrating the durability of the therapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.